Although EntreMed Inc. is now best known for developing anti-angiogenic molecules such as endostatin, the company did not actually begin life with the goal of commercializing that molecule, which sparked a huge run on the company's stock in May 1998, while it was still being tested in mice as an anti-tumor agent.
TheraMed Inc.
To carry on work focusing on the oxygen-delivering capacity of red blood cells, EntreMed Inc, (best known for its anti-angiogenic molecules) created spin-off TheraMed Inc. TheraMed has developed a prototype device and is experimenting with different sorts of reagents, which it believes will enable the three basic sorts of blood cells--platelets, red cells and white blood cells--to be transformed into delivery vehicles for oxygen, drugs, and genes.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
• By
In this week's episode: 2024’s top-selling drugs; two CEOs call for higher Europe drug prices; diabetes trial win for Lilly’s orforglipron; BMS trial failure in schizophrenia; and an analysis of alliance deal-making last year.
• By
Bristol’s CEO Christopher Boerner says business development is the company’s biggest spending priority as analysts raise concerns about growth, citing a need for BMS to do more deals.